AIM ImmunoTech Inc. 8-K

What Happened AIM ImmunoTech, Inc. (AIM) filed a Form 8-K on January 12, 2026 (Item 7.01) to furnish its "AIM January 2026 Corporate Presentation" as Exhibit 99.1. The company notes the presentation is "furnished" — not "filed" — and therefore not subject to Section 18 liability; it includes forward-looking statements about the company’s work with Ampligen® across viral diseases, cancers, and immune-deficiency disorders. The filing also includes a caution that results from animal models and preliminary human studies may not predict future human clinical outcomes and directs investors to review the company's risk factors in its Form 10-K and subsequent 10-Qs.

Key Details

• Filing date: January 12, 2026 (Form 8-K, Item 7.01 and Item 9.01 exhibits).
• Exhibit furnished: 99.1 — "AIM January 2026 Corporate Presentation" (and Inline XBRL cover page, Exhibit 104).
• Disclosure: Presentation contains forward-looking statements protected by the Private Securities Litigation Reform Act safe harbor; company does not undertake to update them after the presentation date.
• Clinical focus noted: Ongoing efforts to evaluate Ampligen® in multiple viral diseases, cancers, and immune-deficiency disorders; additional testing and human trials are required.

Why It Matters For investors, the 8-K signals AIM is providing an updated investor presentation with statements about its pipeline and planned activities for Ampligen. Because the presentation is furnished (not filed) and contains forward-looking statements, it informs but does not change legal disclosure obligations; investors should consult the company’s SEC filings (Form 10-K/10-Q) and the presentation itself for details and to assess risks and timelines for any clinical or regulatory milestones.